Lilly’s Application For Once-Monthly Zyprexa Is Pending At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Olanzapine depot is expected to get a standard 10-month review following submission of an NDA in the second quarter, Lilly says.
You may also be interested in...
Zyprexa Adhera Gets Advisory Committee Review Feb. 6
Incidence of somnolence seen with the long-acting version of Lilly’s atypical antipsychotic will be among the topics discussed.
Zyprexa Adhera Gets Advisory Committee Review Feb. 6
Incidence of somnolence seen with the long-acting version of Lilly’s atypical antipsychotic will be among the topics discussed.
Lilly Zyprexa "Dear Doctor" Letter Warns Of Diabetes Risk
The letter notes that FDA has requested an atypical antipsychotics class warning describing the increased risk of hyperglycemia and diabetes.